Similar articles for PMID: 20072130

Year	Number of Results
2002	1
2005	3
2006	1
2007	1
2008	4
2009	10
2010	12
2011	5
2012	6
2013	4
2014	4
2015	6
2016	6
2017	4
2018	4
2019	3
2020	2
2024	0

1

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.

2

Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.

Zhang J, Jiang W, Liu W, Wu JJ, Song L, Cheng JX, Yao M, Yang LP, Yao DF. Zhang J, et al. Future Oncol. 2016 Feb;12(4):515-24. doi: 10.2217/fon.15.248. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776341

3

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A. Hoang B, et al. Blood. 2010 Nov 25;116(22):4560-8. doi: 10.1182/blood-2010-05-285726. Epub 2010 Aug 4. Blood. 2010. PMID: 20686120 Free PMC article.

4

mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.

Gordeev SA, Bykova TV, Zubova SG, Bystrova OA, Martynova MG, Pospelov VA, Pospelova TV. Gordeev SA, et al. Oncotarget. 2015 Dec 29;6(42):44905-26. doi: 10.18632/oncotarget.6457. Oncotarget. 2015. PMID: 26636543 Free PMC article.

5

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Feldman ME, et al. PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038. PLoS Biol. 2009. PMID: 19209957 Free PMC article.

6

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA. Tasian SK, et al. Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24. Blood. 2017. PMID: 27777238 Free PMC article.

7

ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.

Neil J, Shannon C, Mohan A, Laurent D, Murali R, Jhanwar-Uniyal M. Neil J, et al. Int J Oncol. 2016 Mar;48(3):1045-52. doi: 10.3892/ijo.2015.3311. Epub 2015 Dec 28. Int J Oncol. 2016. PMID: 26719046

8

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

Feldman ME, Shokat KM. Feldman ME, et al. Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.

9

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

Weigelt B, Warne PH, Downward J. Weigelt B, et al. Oncogene. 2011 Jul 21;30(29):3222-33. doi: 10.1038/onc.2011.42. Epub 2011 Feb 28. Oncogene. 2011. PMID: 21358673

10

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A. Yu K, et al. Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584280

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

67 results

Results by year